Related Experiment Video
Updated: Jun 21, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Targeting the JAK2/STAT3 axis in Alzheimer's disease
Tomohiro Chiba1, Marina Yamada, Sadakazu Aiso
1Keio University School of Medicine, Department of Anatomy, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. chibat@sc.itc.keio.ac.jp
Background:
Amyloid beta (Abeta) has long been implicated in the pathogenesis of Alzheimer's disease (AD). Little is known, however, about the intracellular events in neurons which lead to memory loss related to AD. Focusing on the fact that an AD-specific neuroprotective peptide named humanin (HN) inhibits AD-related neurotoxicity by activating the JAK2/STAT3 signaling axis, we recently found that age- and disease-dependent deterioration in the JAK2/STAT3 axis plays a critical role in the pathogenesis of AD.
Objective/Methods:
Here we summarize the neuroprotective effect of HN and its derivative, named colivelin (CLN), and also review the roles of the JAK2/STAT3 axis in memory impairment related to AD.
Results/Conclusions:
The JAK2/STAT3 axis is a major transducer of HN-mediated neuroprotective activity. Abeta-dependent inactivation of the JAK2/STAT3 axis in hippocampal neurons causes cholinergic dysfunction via pre- and post-synaptic mechanisms, which leads to memory impairment related to AD. This provides not only a novel pathological hallmark of AD but also a novel target in AD therapy.
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer Disease ll: Pathophysiology
The JAK-STAT Signaling Pathway
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
PI3K/mTOR/AKT Signaling Pathway